

# Voice Tremor and Botulinum Neurotoxin Therapy

Subjects: [Otorhinolaryngology](#) | [Neurosciences](#)

Contributor: David P. Newland , Daniel Novakovic , Amanda L. Richards

Voice tremor is a common, yet debilitating symptom for patients suffering from a number of tremor-associated disorders. The key to targeting effective treatments for voice tremor requires a fundamental understanding of the pathophysiology that underpins the tremor mechanism and accurate identification of the disease in affected patients. An updated review of the literature detailing the current understanding of voice tremor (with or without essential tremor), its accurate diagnosis and targeted treatment options was conducted, with a specific focus on the role of botulinum neurotoxin. Judicious patient selection, following detailed characterisation of voice tremor qualities, is essential to optimising treatment outcomes for botulinum neurotoxin therapy, as well as other targeted therapies. Further focused investigation is required to characterise the response to targeted treatment in voice tremor patients and to guide the development of innovative treatment options.

voice tremor

essential tremor

botulinum neurotoxin

movement disorders

larynx

dysphonia

## 1. Introduction

Affecting 1–5% of the general population, essential tremor (ET) is the most common movement disorder <sup>[1]</sup>. Despite being so common, because ET is a clinical diagnosis and the spectrum of tremor-associated disorders frequently overlap <sup>[2][3][4]</sup>, this poses challenges for the treating clinician and therefore typically makes ET a diagnosis of exclusion. In 2018, the International Parkinson and Movement Disorder Society (IPMDS) proposed updated diagnostic criteria for ET, including the following four features—isolated tremor consisting of bilateral upper limb action tremor without other motor abnormalities; present for at least three years; with or without head, voice or lower limb tremor; absence of other neurologic signs such as dystonia, ataxia or parkinsonism. Isolated voice tremor is now removed from the essential tremor classification <sup>[5]</sup>. As such, studies pre-reclassification will be herewith referred to with nomenclature that is appropriate to the period in which they were classified.

Essential voice tremor (EVT), previously described as the laryngological manifestation of ET, is present in 18–30% of ET patients <sup>[6]</sup>, as the third most common tremor site after the hands and head <sup>[7]</sup>. EVT typically presents with tremor associated with increased phonatory effort <sup>[8]</sup>. Prior to reclassification, studies report that EVT may be present in the absence of any other manifestations of ET <sup>[9]</sup>; however, a more recent consensus statement proposed updated diagnostic criteria which state that isolated voice or head tremor are not sufficient for a diagnosis of ET <sup>[5]</sup>. ET is independently associated with the female gender <sup>[10][11]</sup>. The disease may be familial—showing an

autosomal-dominant inheritance pattern with reduced penetrance—or sporadic, but no key neurophysiologic or monogenic form has been identified [2][12][13]. Genome-wide association studies (GWAS) have identified an association between a genetic polymorphism involving the gene that encodes the LINGO1 protein [14], which plays important roles in inhibiting cell differentiation, axonal regeneration and synaptic plasticity [4]. The peak onset of ET occurs around the fifth to sixth decades of life and symptom progression typically occurs with age [4][7][12]; however, familial and alcohol-responsive forms of ET may exhibit an earlier onset [2]. While symptoms typically worsen gradually, they may be exacerbated by other physiological or psychological stressors, including exercise, fatigue or stress.

The underlying pathophysiology of ET involves both cerebellar and brainstem dysfunction [15]. This is supported clinically in the manifestation of non-tremor symptoms of ET including gait ataxia, oculomotor abnormalities, mood disturbance and motor learning issues [16]. Neurodegenerative changes occur in the brainstem and cerebellar dentate nucleus [17], with consequent GABAergic dysfunction involving the cerebellum and locus coeruleus and subsequent tremulous activity within the cerebello-thalamo-cortical circuit has been identified [18]. Pathologic Purkinje cell axonal swellings representing damage to Purkinje cell axons have been identified both in the cerebellar vermis and hemispheres [7][10]. As previously described, understanding the pathophysiology of EVT requires consideration of the interplay between the intrinsic disease state and the central neural pathways involved in voice production, as well as the modulatory roles of oral, pharyngeal and pulmonary structures [7][11]. While differences between the neural pathways involved in innate and learned vocalisation are recognised, there is involvement of the primary motor area, superior temporal gyrus, anterior insular cortex, anterior cingulate cortex, basal ganglia, periaqueductal gray and cerebellum [19]. Specifically, structural neuroimaging and post-mortem histopathological studies of head and voice tremor patients demonstrate increased atrophy of the cerebellar vermis, consistent with known cerebellar somatotopic organisation [16][20]. However, more widespread neurodegenerative changes affecting both white and grey matter in many cortical, subcortical and brainstem structures have also been described in ET [15]. It was previously proposed that head and voice tremor may represent distinct subtypes of ET [10], and this is reflected in the updated classification.

The clinical assessment of the tremor patient should rely on characterisation of tremor phenomenology—either in isolation, or in combination with other movement disorders. Key features of the history in patients with suspected ET include the age of onset and family history of tremor, dystonia, parkinsonism, ataxia and dementia [2][21]. Voice complaints are frequently an early presenting symptom of neurological disorders [22].

## 2. Characteristics of Tremor

Understanding tremor aetiology involves detailed characterisation of its qualities. These include the frequency and distribution of the tremor, whether there is unilateral or bilateral involvement, the presence of rest, postural and kinetic elements of the tremor, and whether the tremor exhibits task specificity. The regular tremor of ET characteristically ranges from 4 to 10 Hz; however, significant variability may exist [11][23]. Compared with the predominantly resting tremor of Parkinson disease, ET has both greater postural and kinetic elements; however, 20% of ET patients exhibit resting tremor [11]. Unlike spasmodic dysphonia (SD), EVT is both regular and

directionally symmetric [24]. Anatomically speaking, EVT may be produced by multiple different sources, including the articulatory system (including the jaw, tongue and lips), the respiratory system and the phonatory system [7][25], which may reveal tremor in up to 40% of ET patients [26], and it should be noted that head and voice tremor also frequently co-exist. Close attention should be paid to the neck, particularly the extrinsic laryngeal musculature [7]. Under flexible transnasal laryngoscopic assessment, in the awake, unsedated patient without topical anaesthesia, respiration, sustained vowel phonation, connected speech and maximum phonation time are assessed [7][27]. Patients with EVT are typically affected at multiple laryngeal subsites, with large-series data demonstrating true vocal fold (horizontal) tremor in 100%, supraglottic tremor in 95% and global laryngeal (vertical) tremor in 85% of cases [7][22]. Palatal, tongue base and pharyngeal wall involvement are also frequently seen. Characterising both the location and directionality of the tremor is important in EVT, and vocal tremor severity correlates with increasing subsite involvement, tremor severity of the supraglottis and vertical laryngeal movement [7][26].

### 3. Tools for Detailed Investigative Analysis of Essential Voice Tremor

Both patient self-evaluation of their voice using a self-administered questionnaire such as the abbreviated Voice Handicap Index (VHI-10) [28] and use of a validated outcome measure for perceptual evaluation such as the Voice Perceptual Profile [29] or the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) questionnaire [30] will allow for pre- and post-treatment assessment. Rating scales such as the Vocal Tremor Scoring System (VTSS) [31] and acoustic analysis [32] allow for detailed analysis of the site and severity of the tremor. The VTSS details the severity of tremor across six anatomic subsites based on flexible transnasal laryngoscopic assessment—palate, tongue base, pharyngeal wall, larynx globally, supraglottis and true vocal folds [31]. Specifically, it defines the following: “pharyngeal wall tremor consists of rhythmic medialisation of the lateral wall of the pharynx”; “global laryngeal tremor refers to motion in the vertical dimension of the larynx...relative to the surrounding aerodigestive tract”; “supraglottic tremor...refers to tremor in the anterior-posterior and lateral dimensions of the epiglottis, ventricular folds, aryepiglottic folds and supraglottic portion of the arytenoids”; “true vocal fold tremor refers to activity in the glottal plane consisting of oscillation of the vocal folds in the lateral dimension” [31].

Neurophysiological assessment often plays an important adjunctive role in guiding the treatment of voice disorders and is typically performed using laryngeal electromyography (EMG). Laryngeal EMG involves the use of electrodes to assess the neuromuscular activity of the larynx by recording action potentials within its intrinsic and extrinsic musculature [33]. The electrodes used may be either non-invasive surface electrodes or percutaneous needle electrodes. The electrodes are typically placed using anatomical landmarks and their position verified based on characteristic EMG activity with specific laryngeal activity [33]. The most commonly tested muscles are cricothyroid (CT), thyroarytenoid (TA) and posterior cricoarytenoid (PCA). Laryngeal EMG demonstrates findings of contractile activity during both active and passive laryngeal tasks [9], but may not reliably differentiate EVT from other causes of tremor and is not routinely performed for diagnostic purposes.

### 4. Treatment Options for Essential Voice Tremor

The treatment options for essential voice tremor may be classified as oral pharmacological, non-oral pharmacological and non-pharmacological.

### 4.1. Oral Pharmacological Treatment Options for Essential Voice Tremor

Oral medications are often considered first line in the treatment of EVT. These include propranolol, a non-selective beta-adrenergic receptor antagonist, and primidone, a benzodiazepine. Propranolol acts to reduce adrenergic activity and its lipophilic profile allows a better central effect on the tremor [34], although voice tremor response to propranolol is variable. In a comparison of the effectiveness of onabotulinum toxin Type A and propranolol for EVT [35], 56% of patients reported an improvement in their voice-related quality of life (VRQOL) whilst on propranolol. However, when compared to onabotulinum toxin Type A, propranolol has a lesser effect on VRQOL. The main adverse effects associated with propranolol use include bronchospasm and bradycardia, so careful consideration must be given to their use in patients with comorbid cardiac and respiratory disease. Primidone acts to increase gamma-amino butyric acid (GABA)-A activity and is particularly suited to patients with alcohol-responsive disease, with a response rate in the order of 50% for EVT [7][8]. Owing largely to its common side effects, including fatigue, nausea and malaise, the tolerance of primidone therapy is variable [8]. Other oral medications that have been trialled in the treatment of EVT include methazolamide [36], a carbonic anhydrase inhibitor, and more recently, octanoic acid [37], a derivative of long-chain alcohol 1-octanol—despite showing significant effects on frequency modulation and tremor amplitude, respectively, neither have demonstrated significant subjective symptomatic improvement based on patient-reported outcomes.

### 4.2. Non-Oral Pharmacological Treatment of Essential Voice Tremor

The non-oral pharmacological treatment of EVT involves the use of botulinum neurotoxin (BoNT) injected to a number of different anatomic subsites under laryngeal EMG guidance. While Jankovic and Schwartz first reported the effects of BoNT type A (BoNT-A) treatment in essential tremor in 1991 [38], the first published reports of BoNT-A treatment for EVT were not until 2000 [39]. As previously described, the use of BoNT-A for the treatment of EVT is more effective than propranolol when assessed using a VRQOL questionnaire [35]. More recently, BoNT has become considered part of the standard of care for EVT; however, it should be noted that EVT from palatal, tongue and pharyngeal involvement is considered less responsive to BoNT. The distribution of laryngeal EMG-guided BoNT injections must be correlated to both the direction and location of the tremor in order to achieve the most successful treatment outcome. Whilst glottic incompetence is a common feature of EVT, early data suggest no advantage of augmentation injection laryngoplasty compared with BoNT-A [40].

### 4.3. Treatment of Medically-Refractory Essential Voice Tremor

Second line treatments for medically-refractory EVT include neurostimulatory and ablative options. Both of these treatment options seek to achieve a degree of neuronal inhibition in either the ventral intermediate nucleus (Vim) of the thalamus [23][41] or the caudal zona incerta (cZi) of the basal ganglia [3].

#### 4.3.1. Deep Brain Stimulation for Treatment of Essential Voice Tremor

Deep brain stimulation (DBS) involves surgically implanted electrodes that target different locations within the thalamus and basal ganglia [3]. DBS was first employed as a treatment for essential tremor in 1997 [42] and remains the mainstay of treatment for patients with medically-refractory ET, favoured over the permanent effects of ablative techniques due to its reversible and adjustable nature. DBS may either be unilateral or bilateral. Individual responses to DBS vary and reduction in vocal tremor may be seen in 50 to 95% of patients [3][43]. Stimulation of Vim versus cZi may have differing ET treatment outcomes [44]; however, there is limited evidence directly comparing any difference in treatment response in EVT.

Adverse effects of DBS include dysarthria, sensory disturbances, and gait and balance disturbances; however, these are typically reversible [3][4][45][46]. Adverse effects are more common with bilateral DBS compared with unilateral DBS [47][48].

A proportion of patients treated with DBS for ET also experience waning treatment effects, with multiple postulated mechanisms, including the development of tolerance to neurostimulation and disease progression [49][50].

### 4.3.2. MRI-Guided Thalamotomy for Essential Voice Tremor

Prior to the development of DBS, ablative neurosurgical procedures have been used since the 1950s to create a thalamic or subthalamic lesion for the effective treatment of tremor [51][52]. In 2016, a randomised controlled trial involving 76 participants described the results of the creation of a permanent, unilateral, MRI-guided focused ultrasound (MRgFUS) thalamotomy using focused ultrasound in patients with moderate to severe ET [51]. Subsequent trials have confirmed similar findings [53][54]. Using the validated systems such as the Clinical Rating Scale for Tremor (CRST), the benefits of MRgFUS thalamotomy for ET are sustained for at least 2 years [55][56][57]. Indeed, a recent systematic review found that MRgFUS demonstrates greater improvement in quality of life measures, despite lesser improvement in tremor severity scores compared with DBS [58]. However, just as for DBS, there is very limited published evidence detailing the response of EVT to MRgFUS thalamotomy or with specific focus on vocal tremor outcomes. The most common adverse effects of thalamotomy include gait disturbance and sensory disturbance [56].

## 5. Conclusions

Voice tremor continues to prove an incapacitating symptom for patients. Researchers' ability to target effective treatments relies on a nuanced understanding of the underlying pathophysiology, which continues to be refined. Further investigation is required to optimise researchers' understanding of the disease process in order to improve treatment outcomes for patients with voice tremor.

---

## References

1. Louis, E.D.; Ferreira, J.J. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. *Mov. Disord.* 2010, 25, 534–541.
2. Espay, A.J.; Lang, A.E.; Erro, R.; Merola, A.; Fasano, A.; Berardelli, A.; Bhatia, K.P. Essential pitfalls in “essential” tremor. *Mov. Disord.* 2017, 32, 325–331.
3. Häggglund, P.; Sandström, L.; Blomstedt, P.; Karlsson, F. Voice Tremor in Patients With Essential Tremor: Effects of Deep Brain Stimulation of Caudal Zona Incerta. *J. Voice* 2015, 30, 228–233.
4. Haubenberger, D.; Hallett, M. Essential Tremor. *N. Engl. J. Med.* 2018, 378, 1802–1810.
5. Bhatia, K.P.; Bain, P.; Bajaj, N.; Elble, R.J.; Hallett, M.; Louis, E.D.; Raethjen, J.; Stamelou, M.; Testa, C.M.; Deuschl, G. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. *Mov. Disord.* 2018, 33, 75–87.
6. Lester, R.A.; Barkmeier-Kraemer, J.; Story, B.H. Physiologic and Acoustic Patterns of Essential Vocal Tremor. *J. Voice* 2013, 27, 422–432.
7. Richards, A.L. Vocal tremor: Where are we at? *Curr. Opin. Otolaryngol. Head Neck Surg.* 2017, 25, 475–479.
8. Nida, A.; Alston, J.; Schweinfurth, J. Primidone Therapy for Essential Vocal Tremor. *JAMA Otolaryngol.-Head Neck Surg.* 2015, 142, 117–121.
9. Gurey, L.E.; Sinclair, C.F.; Blitzer, A. A new paradigm for the management of essential vocal tremor with botulinum toxin. *Laryngoscope* 2013, 123, 2497–2501.
10. Chen, W.; Hopfner, F.; Szymczak, S.; Granert, O.; Müller, S.H.; Kühlenbäumer, G.; Deuschl, G. Topography of essential tremor. *Park. Relat. Disord.* 2017, 40, 58–63.
11. Sulica, L.; Louis, E.D. Clinical characteristics of essential voice tremor: A study of 34 cases. *Laryngoscope* 2010, 120, 516–528.
12. Renaud, M.; Marcel, C.; Rudolf, G.; Schaeffer, M.; Lagha-Boukbiza, O.; Chanson, J.-B.; Chelly, J.; Anheim, M.; Tranchant, C. A step toward essential tremor gene discovery: Identification of extreme phenotype and screening of HTRA2 and ANO3. *BMC Neurol.* 2016, 16, 238.
13. Clark, L.N.; Louis, E.D. Challenges in Essential Tremor Genetics: Les défis de la génétique du tremblement essentiel. *Rev. Neurol.* 2015, 171, 466–474.
14. Stefansson, K.; Stefansson, H.; Steinberg, S.; Petursson, H.; Gustafsson, O.; Gudjonsdottir, I.H.; Jonsdottir, G.A.; Palsson, S.T.; Jonsson, T.; Saemundsdottir, J.; et al. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. *Nat. Genet.* 2009, 41, 277–279.
15. Cerasa, A.; Quattrone, A. Linking Essential Tremor to the Cerebellum—Neuroimaging Evidence. *Cerebellum* 2015, 15, 263–275.

16. Louis, E.D.; Faust, P.L.; Ma, K.J.; Yu, M.; Cortes, E.; Vonsattel, J.-P.G. Torpedoes in the Cerebellar Vermis in Essential Tremor Cases vs. Controls. *Cerebellum* 2011, 10, 812–819.
17. Louis, E.D.; Faust, P.L.; Vonsattel, J.-P.G.; Honig, L.S.; Rajput, A.; Robinson, C.A.; Rajput, A.; Pahwa, R.; Lyons, K.E.; Ross, G.W.; et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. *Brain* 2007, 130, 3297–3307.
18. Helmich, R.C.G.; Toni, I.; Deuschl, G.; Bloem, B.R. The pathophysiology of essential tremor and Parkinson's tremor. *Curr. Neurol. Neurosci. Rep.* 2013, 13, 378.
19. Ludlow, C.L. Central nervous system control of voice and swallowing. *J. Clin. Neurophysiol.* 2015, 32, 294–303.
20. Quattrone, A.; Cerasa, A.; Messina, D.; Nicoletti, G.; Hagberg, G.E.; Lemieux, L.; Novellino, F.; Lanza, P.; Arabia, G.; Salsone, M. Essential Head Tremor Is Associated with Cerebellar Vermis Atrophy: A Volumetric and Voxel-Based Morphometry MR Imaging Study. *Am. J. Neuroradiol. AJNR* 2008, 29, 1692–1697.
21. Louis, E.D.; Huey, E.D.; Gerbin, M.; Viner, A.S. Depressive traits in essential tremor: Impact on disability, quality of life, and medication adherence. *Eur. J. Neurol.* 2012, 19, 1349–1354.
22. Aviv, J.E.; Blitzer, A.; Brin, M.F.; Ramig, L.O.; Baredes, S.; Buder, E.H.; Cannito, M.P.; Chhabra, A.; Cooper, D.M.; Cooper, K.A.; et al. *Neurologic Disorders of the Larynx*, 2nd ed.; Georg Thieme: Stuttgart, Germany, 2009.
23. Ravikumar, V.K.; Ho, A.L.; Parker, J.J.; Erickson-DiRenzo, E.; Halpern, C.H. Vocal tremor: Novel therapeutic target for deep brain stimulation. *Brain Sci.* 2016, 6, 48.
24. Louis, E.D. Twelve clinical pearls to help distinguish essential tremor from other tremors. *Expert Rev. Neurother.* 2014, 14, 1057–1065.
25. Fraile, R.; Godino-Llorente, J.I.; Kob, M. Simulation of tremulous voices using a biomechanical model. *EURASIP J. Audio Speech Music Process.* 2015, 2015, 1.
26. Hemmerich, A.L.; Finnegan, E.M.; Hoffman, H.T. The Distribution and Severity of Tremor in Speech Structures of Persons with Vocal Tremor. *J. Voice* 2017, 31, 366–377.
27. de Moraes, B.T.; de Biase, N.G. Laryngoscopy evaluation protocol for the differentiation of essential and dystonic voice tremor. *Braz. J. Otorhinolaryngol.* 2016, 82, 88–96.
28. Rosen, C.A.; Lee, A.S.; Osborne, J.; Zullo, T.; Murry, T. Development and Validation of the Voice Handicap Index-10. *Laryngoscope* 2004, 114, 1549–1556.
29. Oates, J.; Russell, A. Learning voice analysis using an interactive multi-media package: Development and preliminary evaluation. *J. Voice* 1998, 12, 500–512.

30. Kempster, G.B.; Gerratt, B.R.; Verdolini Abbott, K.; Barkmeier-Kraemer, J.; Hillman, R.E. Consensus Auditory-Perceptual Evaluation of Voice: Development of a Standardized Clinical Protocol. *Am. J. Speech-Lang. Pathol.* 2009, 18, 124–132.
31. Bové, M.; Daamen, N.; Rosen, C.; Wang, C.-C.; Sulica, L.; Gartner-Schmidt, J. Development and Validation of the Vocal Tremor Scoring System. *Laryngoscope* 2006, 116, 1662–1667.
32. Haubenberger, D.; Abbruzzese, G.; Bain, P.G.; Bajaj, N.; Benito-León, J.; Bhatia, K.P.; Deuschl, G.; Forjaz, M.J.; Hallett, M.; Louis, E.D.; et al. Transducer-based evaluation of tremor. *Mov. Disord.* 2016, 31, 1327–1336.
33. Heman-Ackah, Y.D.M.D.; Mandel, S.M.D.; Manon-Espaillet, R.M.D.; Abaza, M.M.M.D.; Sataloff, R.T.M.D.D.M.A. Laryngeal Electromyography. *Otolaryngol. Clin. N. Am.* 2007, 40, 1003–1023.
34. Julius, A.; Longfellow, K. Movement Disorders: A Brief Guide in Medication Management. *Med. Clin. N. Am.* 2016, 100, 733–761.
35. Justicz, N.; Hapner, E.R.; Josephs, J.S.; Boone, B.C.; Jinnah, H.A.; Johns Iii, M.M. Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor. *Laryngoscope* 2016, 126, 113–117.
36. Busenbark, K.; Ramig, L.; Dromey, C.; Koller, W.C. Methazolamide for essential voice tremor. *Neurology* 1996, 47, 1331–1332.
37. Lowell, S.Y.; Kelley, R.T.; Monahan, M.; Hosbach-Cannon, C.J.; Colton, R.H.; Mihaila, D. The Effect of Octanoic Acid on Essential Voice Tremor: A Double-Blind, Placebo-Controlled Study: Effect of Octanoic Acid on EVT. *Laryngoscope* 2019, 129, 1882–1890.
38. Jankovic, J.; Schwartz, K. Botulinum toxin treatment of tremors. *Neurology* 1991, 41, 1185–1188.
39. Hertegård, S.; Granqvist, S.; Lindestad, P.-Å. Botulinum Toxin Injections for Essential Voice Tremor. *Ann. Otol. Rhinol. Laryngol.* 2000, 109, 204–209.
40. Estes, C.; Sadoughi, B.; Coleman, R.; Sarva, H.; Mauer, E.; Sulica, L. A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor. *Laryngoscope* 2018, 128, 437–446.
41. Milosevic, L.; Kalia, S.K.; Hodaie, M.; Lozano, A.M.; Popovic, M.R.; Hutchison, W.D. Physiological mechanisms of thalamic ventral intermediate nucleus stimulation for tremor suppression. *Brain* 2018, 141, 2142–2155.
42. Benabid, A.L.; Pollak, P.; Hoffmann, D.; Gervason, C.; Hommel, M.; Perret, J.E.; de Rougemont, J.; Gao, D.M. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. *Lancet* 1991, 337, 403–406.
43. Kundu, B.; Schrock, L.; Davis, T.; House, P.A. Thalamic Deep Brain Stimulation for Essential Tremor Also Reduces Voice Tremor. *Neuromodulation* 2018, 21, 748–754.



44. Sandvik, U.; Koskinen, L.-O.; Lundquist, A.; Blomstedt, P. Thalamic and Subthalamic Deep Brain Stimulation for Essential Tremor: Where Is the Optimal Target? *Neurosurgery* 2012, 70, 840–845.
45. Flora, E.D.; Perera, C.L.; Cameron, A.L.; Maddern, G.J. Deep brain stimulation for essential tremor: A systematic review. *Mov. Disord.* 2010, 25, 1550–1559.
46. Groppa, S.; Herzog, J.; Falk, D.; Riedel, C.; Deuschl, G.; Volkmann, J. Physiological and anatomical decomposition of subthalamic neurostimulation effects in essential tremor. *Brain* 2014, 137, 109–121.
47. Pahwa, R.; Lyons, K.E.; Jankovic, J.; Wilkinson, S.B.; Simpson, R.K.; Ondo, W.G.; Tarsy, D.; Norregaard, T.; Hubble, J.P.; Smith, D.A.; et al. Long-term evaluation of deep brain stimulation of the thalamus. *J. Neurosurg.* 2006, 104, 506–512.
48. Larson, P.S. Deep Brain Stimulation for Movement Disorders. *Neurotherapeutics* 2014, 11, 465–474.
49. Favilla, C.G.; Ullman, D.; Wagle Shukla, A.; Foote, K.D.; Jacobson IV, C.E.; Okun, M.S. Worsening essential tremor following deep brain stimulation: Disease progression versus tolerance. *Brain* 2012, 135, 1455–1462.
50. Shih, L.C.; LaFaver, K.; Lim, C.; Papavassiliou, E.; Tarsy, D. Loss of benefit in VIM thalamic deep brain stimulation (DBS) for essential tremor (ET): How prevalent is it? *Park. Relat. Disord.* 2013, 19, 676–679.
51. Elias, W.J.; Lipsman, N.; Ondo, W.G.; Ghanouni, P.; Kim, Y.G.; Lee, W.; Schwartz, M.; Hynynen, K.; Lozano, A.M.; Shah, B.B.; et al. A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. *N. Engl. J. Med.* 2016, 375, 730–739.
52. Goldman, M.S.; Kelly, P.J. Stereotactic Thalamotomy for Medically Intractable Essential Tremor. *Stereotact. Funct. Neurosurg.* 1992, 58, 22–25.
53. Gallay, M.N.; Moser, D.; Jeanmonod, D. MR-guided focused ultrasound cerebellothalamic tractotomy for chronic therapy-resistant essential tremor: Anatomical target reappraisal and clinical results. *J. Neurosurg.* 2020, 134, 376–385.
54. Abe, K.; Horisawa, S.; Yamaguchi, T.; Hori, H.; Yamada, K.; Kondo, K.; Furukawa, H.; Kamada, H.; Kishima, H.; Oshino, S.; et al. Focused Ultrasound Thalamotomy for Refractory Essential Tremor: A Japanese Multicenter Single-Arm Study. *Neurosurgery* 2021, 88, 751–757.
55. Sinai, A.; Nassar, M.; Eran, A.; Constantinescu, M.; Zaaroor, M.; Sprecher, E.; Schlesinger, I. Magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: A 5-year single-center experience. *J. Neurosurg.* 2019, 133, 417–424.
56. Wu, P.; Lin, W.; Li, K.H.; Lai, H.-C.; Lee, M.-T.; Tsai, K.W.-K.; Chiu, P.-Y.; Chang, W.-C.; Wei, C.-Y.; Taira, T. Focused Ultrasound Thalamotomy for the Treatment of Essential Tremor: A 2-Year

Outcome Study of Chinese People. *Front. Aging Neurosci.* 2021, 13, 697029.

57. Ito, H.; Yamamoto, K.; Fukutake, S.; Odo, T.; Kamei, T. Two-year Follow-up Results of Magnetic Resonance Imaging-guided Focused Ultrasound Unilateral Thalamotomy for Medication-refractory Essential Tremor. *Intern. Med.* 2020, 59, 2481–2483.
58. Giordano, M.; Caccavella, V.M.; Zaed, I.; Foglia Manzillo, L.; Montano, N.; Olivi, A.; Polli, F.M. Comparison between deep brain stimulation and magnetic resonance-guided focused ultrasound in the treatment of essential tremor: A systematic review and pooled analysis of functional outcomes. *J. Neurol. Neurosurg. Psychiatry* 2020, 91, 1270–1278.

---

Retrieved from <https://encyclopedia.pub/entry/history/show/89576>